Risk factor
Negligible price volatility
Profitability factor
Overvalued vs peers
About
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITD.
Target Price
The average target price of LONN.SW is 645 and suggests 16% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell